147 related articles for article (PubMed ID: 10370189)
1. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention.
Felt O; Furrer P; Mayer JM; Plazonnet B; Buri P; Gurny R
Int J Pharm; 1999 Apr; 180(2):185-93. PubMed ID: 10370189
[TBL] [Abstract][Full Text] [Related]
2. Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle.
Felt O; Baeyens V; Buri P; Gurny R
AAPS PharmSci; 2001; 3(4):E34. PubMed ID: 12066799
[TBL] [Abstract][Full Text] [Related]
3. Chitosan as tear substitute: a wetting agent endowed with antimicrobial efficacy.
Felt O; Carrel A; Baehni P; Buri P; Gurny R
J Ocul Pharmacol Ther; 2000 Jun; 16(3):261-70. PubMed ID: 10872923
[TBL] [Abstract][Full Text] [Related]
4. Ocular contact time of a carbomer gel (GelTears) in humans.
Wilson CG; Zhu YP; Frier M; Rao LS; Gilchrist P; Perkins AC
Br J Ophthalmol; 1998 Oct; 82(10):1131-4. PubMed ID: 9924298
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications.
Guillaumie F; Furrer P; Felt-Baeyens O; Fuhlendorff BL; Nymand S; Westh P; Gurny R; Schwach-Abdellaoui K
J Biomed Mater Res A; 2010 Mar; 92(4):1421-30. PubMed ID: 19358259
[TBL] [Abstract][Full Text] [Related]
6. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers.
Meseguer G; Buri P; Plazonnet B; Rozier A; Gurny R
J Ocul Pharmacol Ther; 1996; 12(4):481-8. PubMed ID: 8951684
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects.
Greaves JL; Wilson CG; Birmingham AT
Br J Clin Pharmacol; 1993 Feb; 35(2):188-92. PubMed ID: 8443038
[TBL] [Abstract][Full Text] [Related]
8. Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect.
Zhang J; Wang S
Int J Pharm; 2009 May; 372(1-2):66-75. PubMed ID: 19437594
[TBL] [Abstract][Full Text] [Related]
9. Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery.
Gupta H; Velpandian T; Jain S
J Drug Target; 2010 Aug; 18(7):499-505. PubMed ID: 20055752
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention.
Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G
Drug Deliv; 2013; 20(7):306-9. PubMed ID: 24044648
[TBL] [Abstract][Full Text] [Related]
11. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies.
Wei G; Xu H; Ding PT; Li SM; Zheng JM
J Control Release; 2002 Sep; 83(1):65-74. PubMed ID: 12220839
[TBL] [Abstract][Full Text] [Related]
12. Clearance characteristics of chitosan based formulations in the sheep nasal cavity.
Soane RJ; Hinchcliffe M; Davis SS; Illum L
Int J Pharm; 2001 Apr; 217(1-2):183-91. PubMed ID: 11292554
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional properties of organic-inorganic hybrid nanocomposites based on chitosan derivatives and layered double hydroxides for ocular drug delivery.
Xu T; Zhang J; Chi H; Cao F
Acta Biomater; 2016 May; 36():152-63. PubMed ID: 26940970
[TBL] [Abstract][Full Text] [Related]
14. Formulation and optimization of levofloxacin loaded chitosan nanoparticle for ocular delivery: In-vitro characterization, ocular tolerance and antibacterial activity.
Ameeduzzafar ; Imam SS; Abbas Bukhari SN; Ahmad J; Ali A
Int J Biol Macromol; 2018 Mar; 108():650-659. PubMed ID: 29199125
[TBL] [Abstract][Full Text] [Related]
15. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin.
Di Colo G; Zambito Y; Burgalassi S; Nardini I; Saettone MF
Int J Pharm; 2004 Apr; 273(1-2):37-44. PubMed ID: 15010128
[TBL] [Abstract][Full Text] [Related]
16. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel.
Gratieri T; Gelfuso GM; de Freitas O; Rocha EM; Lopez RF
Eur J Pharm Biopharm; 2011 Oct; 79(2):320-7. PubMed ID: 21641994
[TBL] [Abstract][Full Text] [Related]
17. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit.
Greaves JL; Wilson CG; Rozier A; Grove J; Plazonnet B
Curr Eye Res; 1990 May; 9(5):415-20. PubMed ID: 2166636
[TBL] [Abstract][Full Text] [Related]
18. A comparative study on the efficiency of chitosan-N-acetylcysteine, chitosan oligosaccharides or carboxymethyl chitosan surface modified nanostructured lipid carrier for ophthalmic delivery of curcumin.
Li J; Liu D; Tan G; Zhao Z; Yang X; Pan W
Carbohydr Polym; 2016 Aug; 146():435-44. PubMed ID: 27112894
[TBL] [Abstract][Full Text] [Related]
19. In vivo eye surface residence determination by high-resolution scintigraphy of a novel ion-sensitive hydrogel based on gellan gum and kappa-carrageenan.
Fernández-Ferreiro A; Silva-Rodríguez J; Otero-Espinar FJ; González-Barcia M; Lamas MJ; Ruibal A; Luaces-Rodríguez A; Vieites-Prado A; Lema I; Herranz M; Gómez-Lado N; Blanco-Mendez J; Gil-Martínez M; Pardo M; Moscoso A; Cortes J; Sánchez-Martínez M; Pardo-Montero J; Aguiar P
Eur J Pharm Biopharm; 2017 May; 114():317-323. PubMed ID: 28189624
[TBL] [Abstract][Full Text] [Related]
20. Transport mechanism of chitosan-N-acetylcysteine, chitosan oligosaccharides or carboxymethyl chitosan decorated coumarin-6 loaded nanostructured lipid carriers across the rabbit ocular.
Li J; Tan G; Cheng B; Liu D; Pan W
Eur J Pharm Biopharm; 2017 Nov; 120():89-97. PubMed ID: 28867370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
